BIOMAT Database Logo BIOMAT Database Logo

Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. 1999

M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

Although common in clinical settings, major depressive disorder with associated anxious symptoms ('anxious depression') has not been well studied in antidepressant clinical trials. The aim of this study was to compare the effects of fluoxetine versus amitriptyline in this group of patients. After a single-blind placebo run-in period of 2 weeks, patients were treated on a double-blind basis with fluoxetine or amitriptyline for 8 weeks. Assessment instruments included: 21-item Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Clinical Global Impressions, Raskin Depression Scale and Covi Anxiety Scale. A total of 157 patients were randomized to either fluoxetine or amitriptyline. Fluoxetine was given at a fixed dose of 20 mg/day and amitriptyline was given in a range of 50-250 mg/day (mean of 138.1 mg/day). Fluoxetine was comparable to amitriptyline in all efficacy measures except the HAMD sleep factor. Unwanted effects were more frequent and more severe in the amitriptyline-treated patients. Fluoxetine was comparably efficacious to amitriptyline in the treatment of major depression with associated anxiety. Since fluoxetine was far better tolerated, it is a promising alternative for this frequent and disabling condition.

UI MeSH Term Description Entries
D008297 Male Males
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000639 Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. Amineurin,Amitrip,Amitriptylin Beta,Amitriptylin Desitin,Amitriptylin RPh,Amitriptylin-Neuraxpharm,Amitriptyline Hydrochloride,Amitrol,Anapsique,Apo-Amitriptyline,Damilen,Domical,Elavil,Endep,Laroxyl,Lentizol,Novoprotect,Saroten,Sarotex,Syneudon,Triptafen,Tryptanol,Tryptine,Tryptizol,Amitriptylin Neuraxpharm,Apo Amitriptyline,Desitin, Amitriptylin,RPh, Amitriptylin
D000929 Antidepressive Agents, Tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. Antidepressants, Tricyclic,Tricyclic Antidepressant,Tricyclic Antidepressant Drug,Tricyclic Antidepressive Agent,Tricyclic Antidepressive Agents,Antidepressant Drugs, Tricyclic,Agent, Tricyclic Antidepressive,Agents, Tricyclic Antidepressive,Antidepressant Drug, Tricyclic,Antidepressant, Tricyclic,Antidepressive Agent, Tricyclic,Drug, Tricyclic Antidepressant,Drugs, Tricyclic Antidepressant,Tricyclic Antidepressant Drugs,Tricyclic Antidepressants

Related Publications

M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
November 1998, Pharmacopsychiatry,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
A double-blind comparison of dothiepin and amitriptyline in the treatment of depression with anxiety.
September 1981, The Journal of the Association of Physicians of India,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
A double-blind comparison of dothiepin and amitriptyline for the treatment of depression with anxiety.
January 1971, Psychopharmacologia,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
A double-blind study of minaprine versus amitriptyline in major depression.
January 1990, Neuropsychobiology,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial.
January 1993, International clinical psychopharmacology,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.
June 2002, Headache,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
A comparison of fluoxetine and amitriptyline in the treatment of major depression.
January 1991, International clinical psychopharmacology,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
Paroxetine versus amitriptyline in patients with recurrent major depression: A double-blind trial.
January 2002, International journal of psychiatry in clinical practice,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.
January 1996, Progress in neuro-psychopharmacology & biological psychiatry,
M Versiani, and A Ontiveros, and G Mazzotti, and J Ospina, and J Dávila, and S Mata, and A Pacheco, and J Plewes, and R Tamura, and M Palacios
A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression.
April 1989, International clinical psychopharmacology,
Copied contents to your clipboard!